Compare PRTS & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTS | CTSO |
|---|---|---|
| Founded | 1995 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto & Home Supply Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 45.7M |
| IPO Year | 2006 | 2008 |
| Metric | PRTS | CTSO |
|---|---|---|
| Price | $0.82 | $0.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $0.50 | ★ $5.38 |
| AVG Volume (30 Days) | ★ 987.0K | 67.9K |
| Earning Date | 06-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $22,503,908.00 |
| Revenue This Year | N/A | $7.29 |
| Revenue Next Year | N/A | $8.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 48.53 |
| 52 Week Low | $0.37 | $0.60 |
| 52 Week High | $1.36 | $1.39 |
| Indicator | PRTS | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 69.09 | 61.97 |
| Support Level | $0.70 | $0.61 |
| Resistance Level | $0.93 | $0.84 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 70.70 | 75.78 |
CarParts.com Inc is an online provider of automotive aftermarket parts and repair information. It serves as an end-to-end solution for automotive repair and maintenance resources, offering a seamless online shopping experience that empowers drivers along every part of their journey. The company principally sells its products to individual consumers through its network of websites and online marketplaces. The company's products consist of collision parts serving the body repair market, engine parts to serve the replacement parts market, and performance parts and accessories.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.